
FDA Clears Novartis Drug Cosentyx As Steroid Alternative for Inflammatory Pain Causing Stiff Shoulders
Summary
The United States Food and Drug Administration has approved the Novartis drug Cosentyx to treat adults suffering from polymyalgia rheumatica. This regulatory decision provides a new alternative for patients who cannot tolerate corticosteroids or do not respond adequately to them. The approval establishes this medication as the first anti-interleukin-17 biologic available for this specific inflammatory condition.
On Tuesday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) Cosentyx (secukinumab) 150 mg to treat adults with polymyalgia rheumatica (PMR) who respond inadequately to corticosteroids or cannot tolerate a corticosteroid taper. The regulatory decision establishes Cosentyx as the first and only anti-interleukin-17 (anti-IL-17) biologic for PMR, giving rheumatologists an alternative to long-term steroid therapy backed by…
Source: Read the full story at Top Stories Feed